EGFR and non-small cell lung carcinoma: Moreover, the gene amplification is detectable in 2–5% of NSCLC at first diagnosis and from 5% to 22% in patients with NSCLC with EGFR mutation following erlotinib/gefitinib and more than 20% of patients affected by lung cancer with brain metastases.